Rodney Sidransky
Emergency Medicine · San Diego, CANPI 1417212739
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 460 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among emergency medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 460 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Lundbeck LLC$853
- Vanda Pharmaceuticals Inc.$787
- Takeda Pharmaceuticals U.S.A., Inc.$704
- Teva Pharmaceuticals USA, Inc.$680
- plus $4K from 21 others
What the payments were for
- Food & beverage$9,30199%
- Education$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,207 |
| AbbVie(2 entities) | 74 | $1,102 |
| Lundbeck LLC | 42 | $853 |
| Vanda Pharmaceuticals Inc. | 39 | $787 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $704 |
| Teva Pharmaceuticals USA, Inc. | 23 | $680 |
| Otsuka America Pharmaceutical, Inc. | 33 | $607 |
| Supernus Pharmaceuticals, Inc. | 20 | $590 |
| Neurocrine Biosciences, Inc. | 15 | $384 |
| Bausch Health US, LLC | 23 | $372 |
| Alkermes, Inc. | 16 | $363 |
| Johnson & Johnson | 14 | $337 |
| Corium, LLC | 12 | $299 |
| Sunovion Pharmaceuticals Inc. | 18 | $255 |
| Indivior Inc. | 13 | $238 |
| Axsome Therapeutics, Inc. | 9 | $202 |
| Merck | 5 | $91 |
| Idorsia Pharmaceuticals US Inc | 5 | $76 |
| Eisai Inc. | 3 | $56 |
| Ironshore Pharmaceuticals Inc. | 3 | $44 |
| Almatica Pharma LLC | 2 | $43 |
| Alfasigma USA, Inc. | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Livanova USA, Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$253
How this compares
$9,410 in reported general payments places this provider in the 95th percentile of 6,006 emergency medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $146,027 |
| Invega SustennaPaliperidone Palmitate | 24 | $86,758 |
| Lurasidone Hcl | 30 | $25,066 |
| Risperdal ConstaRisperidone Microspheres | 20 | $25,061 |
| VraylarCariprazine Hcl | 12 | $18,361 |
| TrintellixVortioxetine Hydrobromide | 19 | $10,847 |
| Quetiapine Fumarate | 84 | $2,509 |
| Aripiprazole | 27 | $1,951 |
| Mirtazapine | 63 | $1,423 |
| Olanzapine | 54 | $1,390 |
| Gabapentin | 94 | $1,280 |
| Trazodone Hcl | 102 | $1,132 |
| Duloxetine Hcl | 33 | $1,098 |
| Haloperidol | 32 | $779 |
| Alprazolam | 66 | $698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $384 | $146,02714 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $337 | $111,81944 claims |
| AbbVieVraylar | $1,102 | $18,36112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $704 | $10,84719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,006 emergency medicine providers in California.
Other emergency medicine in San Diego
- Paul PearigenSan Diego$208K
- Christopher CoyneSan Diego$93K
- Bradley BaileySan Diego$35K
- Andrew DesjardinsSan Diego$35K
- Michael NielsenSan Diego$19K
- Michael BlueLone Pine$915K
- Andrew AccardiEncinitas$383K
- Fredrick Melik-AbrahamianSylmar$354K
- Graham WalkerStanford$309K
- Douglas WhiteOakland$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.